title: 1-substituted 4-aryl-5-pyridinylimidazoles: a new class of cytokine suppressive drugs with low 5-lipoxygenase and cyclooxygenase inhibitory potency.
abstract: A series of 1-alkyl- or -aryl-4-aryl-5-pyridinylimidazoles (A) were prepared and tested for their ability to bind to a recently discovered protein kinase termed CSBP and to inhibit lipopolysaccharide (LPS)-stimulated TNF production in mice. The kinase, CSBP, appears to be involved in a signaling cascade initiated by a number of inflammatory stimuli and leading to the biosynthesis of the inflammatory cytokines IL-1 and TNF. Two related imidazole classes (B and C) had previously been reported to bind to CSBP and to inhibit LPS-stimulated human monocyte IL-1 and TNF production. The members of the earlier series exhibited varying degrees of potency as inhibitors of the enzymes of arachidonic acid metabolism, PGHS-1 and 5-LO. Several of the more potent CSBP ligands and TNF biosynthesis inhibitors among the present series of N-1-alkylated imidazoles (A) were tested as inhibitors of PGHS-1 and 5-LO and were found to be weak to inactive as inhibitors of these enzymes. One of the compounds, 9 (SB 210313) which lacked measureable activity as an inhibitor of the enzymes of arachidonate metabolism, and had good potency in the binding and in vivo TNF inhibition assays, was tested for antiarthritic activity in the AA rat model of arthritis. Compound 9 significantly reduced edema and increased bone mineral density in this model.
authors.affiliation: Department of Medicinal Chemistry, SmithKline Beecham Pharmaceuticals, King of Prussia, Pennsylvania 19406-0939, USA. Jeffrey c boehm@sbphrd.com
authors.forename: J C
authors.initials: JC
authors.lastname: Boehm
authors.forename: J M
authors.initials: JM
authors.lastname: Smietana
authors.forename: M E
authors.initials: ME
authors.lastname: Sorenson
authors.forename: R S
authors.initials: RS
authors.lastname: Garigipati
authors.forename: T F
authors.initials: TF
authors.lastname: Gallagher
authors.forename: P L
authors.initials: PL
authors.lastname: Sheldrake
authors.forename: J
authors.initials: J
authors.lastname: Bradbeer
authors.forename: A M
authors.initials: AM
authors.lastname: Badger
authors.forename: J T
authors.initials: JT
authors.lastname: Laydon
authors.forename: J C
authors.initials: JC
authors.lastname: Lee
authors.forename: L M
authors.initials: LM
authors.lastname: Hillegass
authors.forename: D E
authors.initials: DE
authors.lastname: Griswold
authors.forename: J J
authors.initials: JJ
authors.lastname: Breton
authors.forename: M C
authors.initials: MC
authors.lastname: Chabot-Fletcher
authors.forename: J L
authors.initials: JL
authors.lastname: Adams
mesh_terms: D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000138:chemical synthesis*; D001094:Arachidonate 5-Lipoxygenase / Q000378:metabolism; D016718:Arachidonic Acid / Q000378:metabolism; D001168:Arthritis / Q000188:drug therapy; D015519:Bone Density / Q000187:drug effects; D016861:Cyclooxygenase Inhibitors; D016207:Cytokines / Q000037:antagonists & inhibitors*; D007093:Imidazoles / Q000138:chemical synthesis* / Q000378:metabolism / Q000494:pharmacology; D016859:Lipoxygenase Inhibitors; D051379:Mice; D008807:Mice, Inbred BALB C; D015394:Molecular Structure; D009025:Morpholines / Q000138:chemical synthesis* / Q000378:metabolism / Q000494:pharmacology; D011451:Prostaglandin-Endoperoxide Synthases / Q000378:metabolism; D011494:Protein Kinases / Q000378:metabolism; D051381:Rats; D013329:Structure-Activity Relationship; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors / Q000096:biosynthesis
chemical_list: C101726:1-(3-(4-morpholinyl)propyl)-4-(4-fluorophenyl)-5-(4-pyridyl)imidazole; D000894:Anti-Inflammatory Agents, Non-Steroidal; D016861:Cyclooxygenase Inhibitors; D016207:Cytokines; D007093:Imidazoles; D016859:Lipoxygenase Inhibitors; D009025:Morpholines; D014409:Tumor Necrosis Factor-alpha; D016718:Arachidonic Acid; D001094:Arachidonate 5-Lipoxygenase; D011451:Prostaglandin-Endoperoxide Synthases; D011494:Protein Kinases